Pneumothorax during lenvatinib plus pembrolizumab for recurrent endometrial cancer: A case report

Objective: Pneumothorax is a rare adverse event in cancer treatment. Lenvatinib, a multi-kinase inhibitor with antiangiogenic activity, may cause organ perforation. We present a case of pneumothorax during lenvatinib plus pembrolizumab (LP) therapy for endometrial cancer. Case report: A 63-year-old...

Full description

Bibliographic Details

Published in:	Taiwanese Journal of Obstetrics & Gynecology
Main Authors:	Masahiro Taguchi, Yoshifumi Takahashi, Miku Nakamura, Yuji Takei, Hiroyuki Fujiwara
Format:	Article
Language:	English
Published:	Elsevier 2025-09-01
Subjects:	Angiogenesis Lenvatinib Pembrolizumab Pleurodesis Pneumothorax
Online Access:	http://www.sciencedirect.com/science/article/pii/S1028455925001895